Psychotic Disorders

• Definition: Psychosis is a syndrome — not a diagnosis — of impaired reality testing manifesting as delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms. Psychotic disorders are the DSM-5-TR diagnoses in which these features are primary rather than secondary to a mood episode, substance, or medical illness.
• Why it matters: schizophrenia is among the leading causes of years lived with disability worldwide. Most excess mortality is not from suicide but from premature cardiovascular disease, driven by smoking, sedentary behavior, antipsychotic-induced metabolic syndrome, and under-treatment of ordinary medical problems — life expectancy is reduced by roughly one to two decades. Suicide risk is also substantially higher than in the general population, concentrated early in the illness course.

Epidemiology worth recalling

• Prevalence: schizophrenia affects approximately 1% of the population, with remarkably similar rates across countries and cultures.
• Sex and age of onset: men and women are affected at roughly equal rates, but men present earlier (late teens to early 20s) and women later (late 20s), with a second smaller female peak after age 40 — a stem describing new psychosis in a 45-year-old woman is more plausibly schizophrenia than the same stem in a 45-year-old man, where medical or substance causes rise sharply.
• Prognostic demographics: male sex, early and insidious onset, prominent negative symptoms, poor premorbid functioning, and absent precipitating stressor all predict worse outcome.
• Spectrum framing: the DSM-5-TR schizophrenia spectrum runs from schizotypal personality disorder and delusional disorder through brief psychotic disorder and schizophreniform disorder to schizophrenia and schizoaffective disorder — the boundaries are set by duration and by the relationship of psychosis to mood episodes, not by symptom severity.
• First-episode psychosis is now treated as a distinct clinical entity in U.S. practice, with coordinated specialty care programs targeting the period of untreated psychosis, since longer duration of untreated psychosis correlates with worse functional recovery.

Genetic (non-modifiable)

• Family history: the strongest single predictor. Risk rises with degree of relatedness — highest in a monozygotic co-twin, intermediate in first-degree relatives, near population baseline in third-degree relatives. Heritability estimates are high, but inheritance is polygenic, not Mendelian.
• Copy number variants: 22q11.2 deletion syndrome (DiGeorge/velocardiofacial) carries a strikingly elevated schizophrenia risk — examiners plant conotruncal cardiac defect, hypocalcemia, cleft palate, or nasal speech in the stem.
• Advanced paternal age: increases risk via de novo mutations in paternal germ cells.

Prenatal and perinatal insults (largely non-modifiable at presentation)

• Maternal infection (classically influenza in the second trimester), maternal malnutrition/famine, maternal stress, Rh incompatibility, and obstetric complications causing fetal hypoxia. Each supports the neurodevelopmental hypothesis: an early insult to a genetically vulnerable brain that becomes clinically apparent only after adolescent synaptic pruning.
• Late winter/early spring birth: a small but consistently replicated association, presumed infectious/vitamin D–related.

Modifiable and environmental

• Cannabis use in adolescence: dose-dependent and strongest for high-THC products and early initiation, in genetically predisposed individuals. This is the modifiable exposure examiners most often test.
• Other substances: amphetamines/methamphetamine, cocaine, hallucinogens, synthetic cannabinoids, PCP/ketamine, and high-dose corticosteroids can precipitate or unmask psychosis.
• Urban upbringing, migrant status, and social adversity/childhood trauma: reproducible epidemiologic associations, likely mediated through chronic social defeat and stress-axis activation.

Secondary (medical) causes to exclude before labeling a primary psychotic disorder

• Autoimmune: anti-NMDA receptor encephalitis (young woman, psychiatric prodrome, orofacial dyskinesias, seizures, autonomic instability, ovarian teratoma), SLE, antiphospholipid syndrome.
• Infectious: HSV encephalitis, neurosyphilis, HIV.
• Metabolic/endocrine/nutritional: thyroid disease, hypercalcemia, hepatic or uremic encephalopathy, B12 deficiency, porphyria, Wilson disease.
• Neurologic: temporal lobe epilepsy, Huntington disease, stroke, tumor, dementia with Lewy bodies.

• The neurodevelopmental sequence: a polygenic risk background plus an early insult (prenatal infection, hypoxia, malnutrition) produces abnormal neuronal migration and cortical connectivity. The brain compensates until adolescence, when normal synaptic pruning and myelination of prefrontal circuits strip away excess connections — in the vulnerable brain, pruning is excessive, and the prodrome then declares itself. This explains the characteristic late-adolescent/early-adult onset despite an insult decades earlier.

Dopaminergic circuit logic (why each symptom cluster appears)

• Mesolimbic hyperdopaminergia → aberrant salience: neutral stimuli are tagged as personally meaningful, and the patient constructs a delusion to explain the feeling. This is why positive symptoms respond briskly to D2 blockade.
• Mesocortical hypodopaminergia at the dorsolateral prefrontal cortex → negative and cognitive symptoms (avolition, alogia, impaired working memory), and why D2 antagonists do not fix — and may worsen — these domains.
• Nigrostriatal D2 blockade → drug-induced parkinsonism, dystonia, akathisia, and, after chronic blockade, receptor upregulation/supersensitivity manifesting as tardive dyskinesia.
• Tuberoinfundibular D2 blockade removes dopamine's tonic inhibition of prolactin → hyperprolactinemia with galactorrhea, amenorrhea, gynecomastia, sexual dysfunction, and bone loss.

Glutamate and interneuron dysfunction

• NMDA receptor hypofunction on parvalbumin-positive GABAergic interneurons disinhibits cortical pyramidal glutamatergic output, degrading gamma-band synchrony and downstream dopaminergic regulation. Clinically corroborated by ketamine and PCP, which reproduce positive, negative, and cognitive symptoms — something amphetamine (positive symptoms only) does not.

Structural and functional correlates

• Enlarged lateral and third ventricles with reduced cortical and hippocampal gray matter — a loss of neuropil rather than neuronal death.
• Hypofrontality on functional imaging during executive tasks, mapping onto negative and cognitive symptoms.
• Serotonergic 5-HT2A antagonism by second-generation agents disinhibits nigrostriatal dopamine release, which is the mechanistic reason they cause less extrapyramidal toxicity than high-potency first-generation drugs.

• Auditory hallucinations: the most common modality — running commentary, conversing voices, or command hallucinations. Visual hallucinations should redirect you toward delirium, substance intoxication/withdrawal, or Lewy body disease; olfactory hallucinations toward temporal lobe epilepsy.
• Delusions: persecutory most often, plus ideas of reference, thought insertion, thought broadcasting, and delusions of control — the first-rank phenomena arising from failure to tag self-generated thought as one's own.
• Disorganized speech: loosening of associations, tangentiality, word salad, neologisms, and clang associations.

• The 5 A's — flat Affect, Alogia, Avolition, Anhedonia, Ambivalence — plus asociality. They dominate the prodrome and the residual phase and drive long-term functional disability.

Cognitive symptoms

• Impaired working memory, attention, and executive function, often present before the first psychotic break and the best predictor of vocational outcome.

Motor and physical findings

• Catatonia: waxy flexibility, mutism, negativism, posturing, echolalia, echopraxia, stupor or excitement. Not specific to schizophrenia — it is more common in mood disorders and can be medical.
• Neurologic soft signs and abnormal smooth-pursuit eye movements are subtle trait markers.
• Poor grooming and self-neglect, weight gain and metabolic stigmata once treated, and no fever, no clouding of consciousness — the presence of fever, waxing-and-waning attention, or disorientation argues for delirium or encephalitis, not schizophrenia.

• Diagnosis is clinical: there is no confirmatory laboratory or imaging test for schizophrenia. Testing exists to exclude mimics, so the "gold standard" is the DSM-5-TR criteria applied after a negative medical workup.

DSM-5-TR criteria for schizophrenia

• Criterion A: ≥2 of delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms — each present a significant portion of ≥1 month — and at least one must be delusions, hallucinations, or disorganized speech.
• Criterion B: decline in functioning (work, relationships, self-care).
• Criterion C: continuous disturbance for ≥6 months, including the ≥1-month active phase, with prodromal or residual periods counting toward the total.
• Exclusions: schizoaffective and mood disorder with psychotic features are ruled out because mood episodes, if present, are brief relative to the total duration; the disturbance is not attributable to a substance or another medical condition. If autism spectrum or a communication disorder is present, prominent delusions or hallucinations are required.

Initial workup for a first psychotic episode

• Bedside/labs: vital signs, glucose, CBC, comprehensive metabolic panel (including calcium and liver function), TSH, vitamin B12, HIV, syphilis serology, urine drug screen, and pregnancy test.
• Neuroimaging: MRI (or CT) for new-onset psychosis with focal neurologic findings, seizures, atypical age of onset, or rapid cognitive decline.
• Lumbar puncture, EEG, and anti-NMDA receptor antibodies (serum and CSF) when fever, seizures, orofacial dyskinesias, autonomic instability, or a fulminant course suggests autoimmune encephalitis — pelvic imaging for ovarian teratoma follows a positive result.

Immediate stabilization

• Safety and medical clearance first: assess suicidality, homicidality, and ability to care for self; correct hypoglycemia, hypoxia, and intoxication before attributing symptoms to a primary psychotic disorder.
• Acute agitation: verbal de-escalation, then a first-generation antipsychotic (haloperidol IM) and/or a benzodiazepine (lorazepam IM); a second-generation IM option such as olanzapine or ziprasidone is common. Avoid combining IM olanzapine with parenteral benzodiazepines because of excessive sedation and cardiorespiratory depression.

First-line maintenance therapy (APA 2020 schizophrenia guideline)

• Any antipsychotic — for example the second-generation D2/5-HT2A antagonist risperidone — is recommended, with agent selection driven by side-effect profile, prior response, and patient preference rather than by presumed efficacy differences; large comparative-effectiveness work (CATIE) found no dramatic superiority among non-clozapine agents.
• Continue the same agent for maintenance in patients whose symptoms improved, since discontinuation markedly raises relapse risk.
• Coordinated specialty care — team-based psychosocial care with case management, supported employment/education, and family involvement — is recommended for first-episode psychosis.
• Adjunctive psychosocial treatment: cognitive behavioral therapy for psychosis, psychoeducation, family intervention, assertive community treatment for repeated hospitalization or homelessness.

Escalation

• Inadequate response: verify adherence and adequate dose/duration before switching; a long-acting injectable (paliperidone palmitate, aripiprazole lauroxil, haloperidol decanoate) is recommended when nonadherence drives relapse.
• Treatment-resistant schizophrenia — failure of two adequate antipsychotic trials — mandates clozapine, which APA also recommends for persistent suicidal ideation or aggression in this population.
• Catatonia: benzodiazepine (lorazepam) challenge; ECT for refractory catatonia, and as an option for treatment-resistant psychosis.
• Tardive dyskinesia: VMAT2 inhibitors (valbenazine, deutetrabenazine).

Contraindicated/avoid

• Antipsychotics in dementia-related psychosis carry an FDA boxed warning for increased mortality.
• D2 antagonists in dementia with Lewy bodies or Parkinson disease psychosis — severe neuroleptic sensitivity; use quetiapine or pimavanserin.
• Antipsychotic monotherapy polypharmacy and prophylactic anticholinergics are discouraged; clozapine should not be paired with other marrow-suppressing drugs.

Complications of the disease

• Suicide: highest risk early in illness, in younger patients with preserved insight and depressive symptoms after a psychotic episode. Command hallucinations to self-harm are a psychiatric emergency.
• Premature cardiovascular mortality: from smoking, sedentary lifestyle, and undertreated hypertension/diabetes — the leading cause of death.
• Substance use disorders, especially nicotine (which induces CYP1A2 and lowers clozapine and olanzapine levels — abrupt smoking cessation can precipitate toxicity), cannabis, and alcohol.
• Functional loss: unemployment, homelessness, incarceration, and victimization; patients are far more often victims than perpetrators of violence.
• Water intoxication (psychogenic polydipsia) → hyponatremia, seizures.

Complications of treatment — emergencies first

• Neuroleptic malignant syndrome: idiosyncratic, from abrupt profound D2 blockade — fever, "lead-pipe" rigidity, altered mental status, autonomic instability, markedly elevated CK, leukocytosis. Stop the antipsychotic, cool, hydrate aggressively to prevent rhabdomyolysis-induced acute kidney injury; dantrolene and bromocriptine are adjuncts. Distinguish from serotonin syndrome (hyperreflexia, clonus, diarrhea, rapid onset).
• Clozapine-specific: severe neutropenia/agranulocytosis (ANC monitoring is mandated under the FDA Clozapine REMS), myocarditis (early, with fever, chest pain, eosinophilia, rising troponin), dose-related seizures, orthostatic hypotension, and severe constipation progressing to ileus and bowel perforation — an underappreciated cause of death.
• QT prolongation → torsades: greatest with ziprasidone, IV haloperidol, and thioridazine.
• Acute dystonia (hours to days; torticollis, oculogyric crisis, laryngospasm — treat with anticholinergic benztropine or diphenhydramine) and akathisia (days to weeks; motor restlessness, linked to suicidality — reduce dose, add propranolol).
• Drug-induced parkinsonism (weeks) and tardive dyskinesia (months to years, from D2 receptor supersensitivity; often irreversible).
• Metabolic syndrome: greatest with clozapine and olanzapine — weight gain, dyslipidemia, new diabetes, and hyperosmolar hyperglycemic state.
• Hyperprolactinemia from tuberoinfundibular blockade (risperidone, paliperidone, haloperidol): galactorrhea, amenorrhea, sexual dysfunction, osteoporosis.

• Duration is the whole game: <1 month = brief psychotic disorder; 1–6 months = schizophreniform; ≥6 months = schizophrenia. In schizoaffective disorder, psychosis must persist ≥2 weeks in the absence of a mood episode — that single clause separates it from major depression or bipolar disorder with psychotic features.
• Single best next step in new-onset psychosis is almost never "start an antipsychotic" — it is to exclude medical and substance causes (glucose, metabolic panel, TSH, B12, syphilis and HIV serology, urine drug screen, imaging when indicated).
• The association examiners love: adolescent cannabis use and later schizophrenia in genetically predisposed individuals — dose-dependent and modifiable.
• Young woman with psychiatric symptoms plus orofacial dyskinesias, seizures, and autonomic instability = anti-NMDA receptor encephalitis; look for an ovarian teratoma, not a primary psychotic disorder.
• Two failed adequate antipsychotic trials → clozapine, per the APA schizophrenia guideline; it is also the agent with evidence for reducing suicidality. New fever or flu-like illness in the first weeks of clozapine should prompt evaluation for myocarditis and agranulocytosis, not reassurance.
• Movement side effects by timeline: hours–days = acute dystonia (anticholinergic); days–weeks = akathisia (propranolol); weeks = parkinsonism; months–years = tardive dyskinesia (VMAT2 inhibitor). Anticholinergics do not treat tardive dyskinesia and may worsen it.
• Common distractor: attributing fever plus rigidity to "serotonin syndrome" when the patient is on an antipsychotic — NMS gives lead-pipe rigidity and bradyreflexia; serotonin syndrome gives clonus and hyperreflexia with diarrhea.
• Do not "fix" negative symptoms by raising the D2 blockade — negative and cognitive symptoms reflect mesocortical hypodopaminergia and worsen with more antagonism; escalating dose mainly buys extrapyramidal and prolactin toxicity.

• Psychosis = loss of reality testing (delusions, hallucinations, disorganized speech/behavior, negative symptoms)
• Schizophrenia: 1% prevalence; requires symptoms for ≥6 months (≥1 month active phase); poorer prognosis if male, early onset, insidious onset
• Brief Psychotic Disorder: symptoms 1 day to 1 month; Schizophreniform: 1-6 months; Schizophrenia: ≥6 months
• Psychotic Disorder Due to Medical Condition must be ruled out first (CNS infections, stroke, hypoxia, metabolic derangements)
• Antipsychotics block dopamine D2 receptors; risk of tardive dyskinesia (involuntary movements), NMS, metabolic syndrome

1. 1.Forgetting to rule out medical/substance causes first — Synthetic cannabinoids, amphetamines, steroids, antiparkinsonian agents can cause psychosis; CNS infections/metabolic disorders are medical emergencies
2. 2.Confusing psychotic symptoms with dissociation — Dissociation lacks true loss of reality testing; patient with DID knows voices are "internal"
3. 3.Assuming all antipsychotics are equal — Clozapine most effective for treatment-resistant schizophrenia but requires WBC monitoring; risperidone/olanzapine cause more metabolic effects; aripiprazole is dopamine partial agonist (different MOA)

• Antipsychotics: Risperidone, olanzapine, quetiapine (atypical) for acute/maintenance; start low, titrate slowly to minimize side effects
• Psychosocial: CBT, family therapy, vocational rehabilitation improve outcomes
• Acute agitation: IM haloperidol or lorazepam; monitor for Neuroleptic Malignant Syndrome (fever, rigidity, altered mental status, ↑CK) — STOP antipsychotic, supportive care, dantrolene
• Target: 2-4 weeks for symptom improvement; negative symptoms take longer
• Adherence: Long-acting injectables (paliperidone palmitate) improve compliance